This makes sense. So, Elto was developed by Sol
Post# of 30065
(Total Views: 669)
Posted On: 04/12/2019 1:57:25 PM
This makes sense.
So, Elto was developed by Solvay, who licensed it to PsychoGenics who licensed it to AMBS who dropped it into Elto Pharma. These are all private companies (except Ambs/Elto of course). According to AMBS press release, Elto is a "joint venture of which Amarantus owns approximately 50%" so I guess PsychoGenics owns the other 50% and whatever agreement they have with Solvay is their problem.
Now, on to Coeptis (also private), AMBS has 7.5M of 15M shares outstanding, with "an additional 7.5 million shares being delivered to Elto Pharma shareholders upon the completion of certain milestones." Elto shareholders are... Us and Possibly Chan as well "As part of the agreement, the Company is redeeming the Series F convertible preferred stock and the significant voting rights associated therewith, in exchange for equity in Amarantus, as well as equity in subsidiaries Elto Pharma, Cutanogen Corporation and Breakthrough Diagnostics,."
So, whatever comes from Elto, we sort of end up with 1/2 of it (or of then entire Coeptis pipeline?) with the question of these mysterious shares Chan possibly owns. However, this grand statement about how this "sale" will be worth more than everything AMBS owes is great, but Gerald calls this a sale, when in fact we are acquiring shares in a private company. Do we only make $$ when they IPO (in which case, we wouldn't own all outstanding shares by a long shot) or do we actually own the entire company, or would the plan be to pay a bunch of cash to buy these 'shares' back?
I'm just a tad confused here, and all the Elto talk got me thinking
I
So, Elto was developed by Solvay, who licensed it to PsychoGenics who licensed it to AMBS who dropped it into Elto Pharma. These are all private companies (except Ambs/Elto of course). According to AMBS press release, Elto is a "joint venture of which Amarantus owns approximately 50%" so I guess PsychoGenics owns the other 50% and whatever agreement they have with Solvay is their problem.
Now, on to Coeptis (also private), AMBS has 7.5M of 15M shares outstanding, with "an additional 7.5 million shares being delivered to Elto Pharma shareholders upon the completion of certain milestones." Elto shareholders are... Us and Possibly Chan as well "As part of the agreement, the Company is redeeming the Series F convertible preferred stock and the significant voting rights associated therewith, in exchange for equity in Amarantus, as well as equity in subsidiaries Elto Pharma, Cutanogen Corporation and Breakthrough Diagnostics,."
So, whatever comes from Elto, we sort of end up with 1/2 of it (or of then entire Coeptis pipeline?) with the question of these mysterious shares Chan possibly owns. However, this grand statement about how this "sale" will be worth more than everything AMBS owes is great, but Gerald calls this a sale, when in fact we are acquiring shares in a private company. Do we only make $$ when they IPO (in which case, we wouldn't own all outstanding shares by a long shot) or do we actually own the entire company, or would the plan be to pay a bunch of cash to buy these 'shares' back?
I'm just a tad confused here, and all the Elto talk got me thinking
I
(1)
(0)